[Antigenicity study of trandolapril (RU44570)]

Area of Science:

• Immunology
• Pharmacology

Context:

• Trandolapril is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension.
• Evaluating the antigenicity of pharmaceutical compounds is crucial for drug safety and to prevent immunogenic reactions.

Purpose:

• To comprehensively assess the antigenicity of trandolapril (RU44570) using a battery of immunological tests.
• To determine if trandolapril elicits immediate or delayed hypersensitivity reactions.

Summary:

• Six distinct immunological assays were employed: active systemic anaphylaxis (ASA), passive cutaneous anaphylaxis (PCA) in guinea pigs and rats, histamine release from lung tissue, Schultz-Dale reaction, and delayed type skin reactions.
• Sensitization protocols involved oral, subcutaneous, and intraperitoneal administration of trandolapril, often with adjuvants like Freund's complete adjuvant (FCA) or alum.
• Across all tested models and methods, trandolapril (RU44570) did not induce any observable anaphylactic symptoms, histamine release, tissue contraction, or skin reactions, indicating a lack of antigenicity.

Impact:

• The study concludes that trandolapril (RU44570) exhibits no significant antigenicity under the tested experimental conditions.
• These findings support the safety profile of trandolapril concerning immunogenic potential.
• Provides essential data for regulatory assessment and clinical use of trandolapril.